

**Comprehensive
screening of *Aconitum*
alkaloids in Kampo
herbal medicine, in
human serum and
urine by high
resolution LC/TOF
Mass Spectrometry**

ASMS 2010


Masahiko Takino¹, Makiko Hayashida² and
Youkichi Ohno² ¹Agilent Technologies
Japan, Ltd, ²Department of Legal Medicine,
Nippon Medical School



Comprehensive screening of Aconitium alkaloids in Kampo herbal medicine, in human serum and urine by high resolution LC/TOF Mass Spectrometry

Introduction

The root of *Aconitium carmichaeli* (Fig.1) is called Bushi or Uzu and widely used as traditional herbal medicine in both China and Japan. However, it is a highly toxic herbal medicine because of the presence of diterpene alkaloids such as aconitine, mesaconitine, hypaconitine and jesaconitine. These alkaloids share a common C19 norditerpenoid skeleton and divided into four types, named as non ester diterpene alkaloids, monoester diterpene alkaloids, diester diterpene alkaloids (Fig.2) and lipoalkaloids. Kampo herbal medicine contained Uzu is hydrolyzed to the non ester and mono ester diterpene alkaloids and detoxified by decocting in boiling water. However, there are several reports of patients who had taken Kampo herbal medicine and developed symptoms of aconite intoxication. The adverse reactions caused by Kampo herbal medicine may originate from adulteration, misidentification, variability in the amount of active ingredients, and improper processing and preparation. Therefore, to guarantee the safety and efficacy of use of aconitum type of Kampo herbal medicine the first prerequisite is to apply comprehensive analytical methods to monitor a large set of active ingredients, i.e. mainly alkaloids. This work describes a novel comprehensive screening method for 11 known *aconitum* alkaloids and other components in Kampo herbal medicine, human serum and urine using high resolution LC/TOFMS and exact mass and retention time(option) database.



| Compounds | R ₁ | R ₂ | R ₃ | MW |
|--------------------|-------------------------------|----------------|--|-----|
| Aconitine | C ₂ H ₅ | OH | H | 645 |
| Mesaconitine | CH ₃ | OH | H | 631 |
| Hypaconitine | CH ₃ | H | H | 615 |
| Jesaconitine | C ₂ H ₅ | OH | OCH ₃ | 675 |
| Benzoylaconine | C ₂ H ₅ | OH | COC ₆ H ₅ | 603 |
| Benzoylmesaconine | CH ₃ | OH | COC ₆ H ₅ | 589 |
| Benzoylhypaconine | CH ₃ | H | COC ₆ H ₅ | 573 |
| 1,4-Anisoylaconine | C ₂ H ₅ | OH | COC ₆ H ₅ OCH ₃ | 633 |
| Aconine | C ₂ H ₅ | OH | H | 499 |
| Mesaconine | CH ₃ | OH | H | 485 |
| Hypaconine | CH ₃ | H | H | 469 |

Fig.2 *Aconitium* alkaloids and metabolites of *Aconitium* alkaloids

Experimental

Table 1. Experimental conditions for LC/TOF-MS

| | |
|---------------|--|
| HPLC | : Agilent 1200 |
| Column | : ZORBAX Eclipse Plus C18(100mm,2.1mm,1.8um) |
| Oven temp | : 40 C |
| Mobile phase | : A=ACN , B=0.1%HCOOH+10mMHCOONH ₄ 5%A---(20min)---45%B---(5min)---100%B |
| Flow rate | : 0.2 mL/min |
| Injection | : 5 µL |
| MS | : Agilent 6520 Q-TOF LC-MS |
| Ionization | : ESI (positive ion mode) |
| Nebulizer gas | : 345 kPa |
| Dry gas | : 10 L/min at 350C |
| Mass range | : 100-1000Da |
| Reference | : $m/z=112.050873$, $m/z=922.009798$ |
| Resolution | : >10000 at $m/z=121$ |

Sample preparation

Detoxified Buhi, Uzu, urine, serum and gastric contents (GS) of patient samples were prepared using Solid Phase Extraction (SPE). The scheme is shown in Fig.3




Fig.3 Sample preparation scheme

Screening target compounds by exact mass database

Extracts were analyzed by LC/TOF-MS and 11 target *aconitum* alkaloids were screened using an exact mass and retention time database with the parameters shown in Tables 2

Table.2 Target screening parameter

| | |
|-----------------------|----------------------|
| Target mass | : (M+H) ⁺ |
| Charge | : Single charge ion |
| Mass window | : 0.01Da |
| Retention time window | : 1 min |
| Relative mass error | : 5 ppm |

Results and Discussion

Analysis of 11 aconitum alkaloid standards

11 *aconitum* alkaloids and metabolite standards shown in Fig.2 were analyzed to construct exact mass and retention time database for target screening. Extract ion chromatograms (EICs) and mass spectra of these compounds are shown in Fig.4.

Target screening of 11 *aconitum* alkaloids

Extracts of the detoxified Bushi, Uzu, urine, serum and GS of the patient were analyzed. 11 *aconitum* alkaloids (Fig.4) were searched by using exact mass and retention time database. Mass chromatograms of 11 target alkaloids are shown in Fig.5. Abundance and relative mass error of each aconitum alkaloid are shown in Table 3.




Fig.4 EICs and mass spectra of 11 *aconitum* alkaloids




Fig.5 EICs of *aconitum* alkaloids in each extract

Results and Discussion

Table 3. Abundance and relative mass error of each *aconitum* alkaloid.

Non-target screening of *aconitum* alkaloids

15 alkaloids and 12 lipo-alkaloids were searched using exact mass database. Mass chromatograms are shown in Fig.6. Abundance and relative mass error of each compound are shown in table 4.




Fig.6 EICs of detected 19 components in each extract

Table 4. Abundance and relative mass error of each components.

Conclusions

- 11 target *aconitum* alkaloids gave protonated molecules as the base ion in the mass spectrum with relative mass errors of less than 3 ppm.
- All target alkaloids were detected in detoxified Bushi and Uzu. However, amounts of diester alkaloids in detoxified Bushi were less than 10% of the levels found in Uzu.
- All diester alkaloids were detected in urine, serum and gastric contents of the patient.
- 15 alkaloids and 4 lipo-alkaloids were identified in detoxified Bushi and Uzu using an exact mass database with less than 5 ppm error.
- 4 lipo-alkaloids were detected in only gastric contents of the patient.
- We have demonstrated that the use of LC-QToF together with an accurate mass database can be used to screen for targeted alkaloid compounds in herbal samples.